テセントリク（アテゾリズマブ）の世界市場レポート2025年：疫学、パイプライン分析、市場インサイトと予測

テセントリク（アテゾリズマブ）の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR12%で68億5,000万米ドルに成長します。予測期間の成長は、早期発見と予防への注目の高まり、がん生存率の上昇、世界のがん研究イニシアチブの拡大、新興経済諸国における医療支出の増加、患者や医師の意識の高まりなどに起因しています。予測期間における主要動向には、人工知能（AI）の統合、遠隔医療と遠隔モニタリング、規制改革、バイオマーカー発見の進歩、革新的な医薬品開発などがあります。

がんの有病率の増加がテセントリク（アテゾリズマブ）市場の成長を促進すると予想されます。このようながん患者の増加は、高齢化、検出技術の向上、ライフスタイルの変化、環境暴露、生存率の向上などの要因によるもので、これらすべてががんと診断され、がんと共に生きる人々の増加に寄与しています。テセントリク（アテゾリズマブ）は、腫瘍が免疫の検出を回避することを可能にするタンパク質であるPD-L1を阻害することにより、免疫系を利用してがんと闘うため、がん治療には不可欠です。これにより、免疫系のT細胞ががん細胞をより効果的に認識し、破壊することが可能になります。例えば、2024年1月、米国がん協会は、がん患者の増加を報告し、新規患者数は2023年の195万8310人から201万1140人に増加し、2.19％の伸びを示しました。その結果、がんの有病率の増加がテセントリク（アテゾリズマブ）市場を前進させています。

テセントリク（アテゾリズマブ）市場の主要動向は、正確な投与、迅速な全身吸収、安定した治療レベルの確保を目的としたアテゾリズマブの静脈内投与製剤などの革新的製品の開発です。点滴静注製剤は、液状製剤を点滴により直接血流に投与するもので、全身がん治療のためにモノクローナル抗体を効率的に投与できるように設計されています。例えば、2024年9月、Genentech Inc.はアテゾリズマブとヒアルロニダーゼ-tqjsの皮下注射の承認を米国食品医薬品局から取得しました。テセントリクは、米国で承認された最初の皮下注射用抗PD-L1療法であり、IMscin001検査で実証されたように、薬剤曝露量と全奏効率において同等の有効性を維持しながら、静脈内注入に必要な30～60分と比較して約7分という迅速な投与時間という明確な利点を記載しています。IMscin001は、NSCLC、SCLC、メラノーマ、肝細胞がん、肺胞軟部肉腫を含む様々な成人がんに対して承認されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のテセントリク（アテゾリズマブ）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のテセントリク（アテゾリズマブ）市場：成長率分析
• 世界のテセントリク（アテゾリズマブ）市場の実績：規模と成長、2019～2024年
• 世界のテセントリク（アテゾリズマブ）市場の予測：規模と成長、2024～2029年、2034年
• 世界のテセントリク（アテゾリズマブ）：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のテセントリク（アテゾリズマブ）市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• PD-L1阻害剤
• PD-1阻害剤
• CTLA-4阻害剤
• 免疫調節薬
• その他
• 世界のテセントリク（アテゾリズマブ）市場：疾患別、実績と予測、2019～2024年、2024～2029年、2034年
• 肺がん
• 膀胱がん
• 黒色腫
• ホジキンリンパ腫
• 頭頸部がん
• その他
• 世界のテセントリク（アテゾリズマブ）市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のテセントリク（アテゾリズマブ）市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 在宅医療
• 専門クリニック
• その他

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のテセントリク（アテゾリズマブ）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のテセントリク（アテゾリズマブ）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• テセントリク（アテゾリズマブ）市場：競合情勢
• テセントリク（アテゾリズマブ）市場：企業プロファイル
  • Roche Holding AG
  • Chugai Pharmaceutical Co. Ltd.

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• テセントリク（アテゾリズマブ）市場、2029年：新たな機会を提供する国
• テセントリク（アテゾリズマブ）市場、2029年：新たな機会を提供するセグメント
• テセントリク（アテゾリズマブ）市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Tecentriq (atezolizumab) is a monoclonal antibody-based immunotherapy that belongs to a class of cancer treatments called immune checkpoint inhibitors. It specifically targets the protein programmed death ligand 1 (PD-L1), blocking the interaction between PD-L1 (found on tumor and immune cells) and PD-1 or B7.1 receptors on T-cells. This inhibition reactivates the immune system, allowing T-cells to recognize and destroy cancer cells.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of tecentriq (atezolizumab) include PD-L1 inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, immunomodulators, and others. Tecentriq PD-L1 Inhibitor is a monoclonal antibody that blocks PD-L1, a protein that suppresses the immune response against cancer cells. It is used for treating lung cancer, bladder cancer, melanoma, Hodgkin's lymphoma, head and neck cancer, and others. Tecentriq is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by different end users such as hospitals, home care providers, specialty clinics, and others.

The tecentriq (atezolizumab) market research report is one of a series of new reports from The Business Research Company that provides tecentriq (atezolizumab) market statistics, including tecentriq (atezolizumab) industry global market size, regional shares, competitors with a tecentriq (atezolizumab) market share, detailed tecentriq (atezolizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the tecentriq (atezolizumab) industry. This tecentriq (atezolizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tecentriq (atezolizumab) market size is expected to see rapid growth in the next few years. It will grow to $6,850 million in 2029 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to increasing focus on early detection and prevention, growing cancer survival rates, expanding global cancer research initiatives, higher healthcare spending in developing economies, growing awareness among patients and physicians. Major trends in the forecast period include integration of artificial intelligence (AI), telemedicine and remote monitoring, regulatory Innovations, advancements in biomarker discovery, innovative drug development.

The increasing prevalence of cancer is expected to drive the growth of the tecentriq (atezolizumab) market. This rise in cancer cases can be attributed to factors such as an aging population, better detection techniques, lifestyle changes, environmental exposures, and improved survival rates, all contributing to more people being diagnosed and living with cancer. Tecentriq (atezolizumab) is vital for cancer treatment as it utilizes the immune system to combat cancer by blocking PD-L1, a protein that allows tumors to evade immune detection. This enables the immune system's T-cells to recognize and destroy cancer cells more effectively. For example, in January 2024, the American Cancer Society reported a rise in cancer cases, with the number of new cases increasing to 2,001,140 from 1,958,310 in 2023, a growth of 2.19%. As a result, the growing prevalence of cancer is driving the tecentriq (atezolizumab) market forward.

A key trend in the tecentriq (atezolizumab) market is the development of innovative products, such as intravenous formulations of atezolizumab, aimed at ensuring precise dosing, rapid systemic absorption, and consistent therapeutic levels. The intravenous formulation is a liquid preparation administered directly into the bloodstream via infusion, designed to efficiently deliver the monoclonal antibody for systemic cancer treatment. For example, in September 2024, Genentech Inc. received approval from the U.S. Food and Drug Administration for atezolizumab and hyaluronidase-tqjs for subcutaneous injection. Tecentriq, the first subcutaneous anti-PD-L1 therapy approved in the U.S., offers a distinct advantage with a faster administration time of approximately 7 minutes compared to the 30-60 minutes required for intravenous infusion, while maintaining comparable efficacy in drug exposure and overall response rates, as demonstrated in the IMscin001 trial. It is approved for various adult cancers, including NSCLC, SCLC, melanoma, hepatocellular carcinoma, and alveolar soft part sarcoma.

In October 2024, Lonza Group AG, a Switzerland-based pharmaceutical, biotechnology, and nutrition company, acquired Roche's Vacaville large-scale biologics manufacturing facility for $1.2 billion. This acquisition establishes a strong West Coast manufacturing presence near the San Francisco biotech hub, complementing Lonza's existing East Coast site in Portsmouth, New Hampshire, and its global network in Europe and Asia Pacific. The expansion significantly strengthens Lonza's ability to manufacture late-stage clinical and commercial products and support the production of new molecules approaching commercialization. Roche Holding AG, a Switzerland-based manufacturer of pharmaceuticals and biologics, produces Tecentriq (atezolizumab).

Major players operating in the tecentriq (atezolizumab) market are Roche Holding AG, and Chugai Pharmaceutical Co. Ltd.

North America was the largest region in the tecentriq (atezolizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tecentriq (atezolizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tecentriq (atezolizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tecentriq (atezolizumab) market consists of sales of biosimilars, immuno-oncology pipeline drugs, supportive oncology medications and related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tecentriq (Atezolizumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tecentriq (atezolizumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tecentriq (atezolizumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tecentriq (atezolizumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: PD-L1 Inhibitors; PD-1 Inhibitors; CTLA-4 Inhibitors; Immunomodulators; Other Drug Classes
• 2) By Clinical Indication: Lung Cancer; Bladder Cancer; Melanoma; Hodgkin's Lymphoma; Head And Neck Cancer; Other Indications
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Companies Mentioned: Roche Holding AG; Chugai Pharmaceutical Co. Ltd
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tecentriq (Atezolizumab) Market Characteristics

3. Tecentriq (Atezolizumab) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Tecentriq (Atezolizumab) Market Trends And Strategies

5. Tecentriq (Atezolizumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Tecentriq (Atezolizumab) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Tecentriq (Atezolizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Tecentriq (Atezolizumab) Market Growth Rate Analysis
• 6.4. Global Tecentriq (Atezolizumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Tecentriq (Atezolizumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Tecentriq (Atezolizumab) Total Addressable Market (TAM)

7. Global Tecentriq (Atezolizumab) Market Pricing Analysis & Forecasts

8. Tecentriq (Atezolizumab) Market Segmentation

• 8.1. Global Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PD-L1 Inhibitors
• PD-1 Inhibitors
• CTLA-4 Inhibitors
• Immunomodulators
• Other Drug Classes
• 8.2. Global Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lung Cancer
• Bladder Cancer
• Melanoma
• Hodgkin's Lymphoma
• Head And Neck Cancer
• Other Indications
• 8.3. Global Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 8.4. Global Tecentriq (Atezolizumab) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users

9. Global Tecentriq (Atezolizumab) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Tecentriq (Atezolizumab) Market Regional And Country Analysis

• 10.1. Global Tecentriq (Atezolizumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Tecentriq (Atezolizumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Tecentriq (Atezolizumab) Market

• 11.1. Asia-Pacific Tecentriq (Atezolizumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Tecentriq (Atezolizumab) Market

• 12.1. China Tecentriq (Atezolizumab) Market Overview
• 12.2. China Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Tecentriq (Atezolizumab) Market

• 13.1. India Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Tecentriq (Atezolizumab) Market

• 14.1. Japan Tecentriq (Atezolizumab) Market Overview
• 14.2. Japan Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Tecentriq (Atezolizumab) Market

• 15.1. Australia Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Tecentriq (Atezolizumab) Market

• 16.1. South Korea Tecentriq (Atezolizumab) Market Overview
• 16.2. South Korea Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Tecentriq (Atezolizumab) Market

• 17.1. Western Europe Tecentriq (Atezolizumab) Market Overview
• 17.2. Western Europe Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Tecentriq (Atezolizumab) Market

• 18.1. UK Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Tecentriq (Atezolizumab) Market

• 19.1. Germany Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Tecentriq (Atezolizumab) Market

• 20.1. France Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tecentriq (Atezolizumab) Market

• 21.1. Eastern Europe Tecentriq (Atezolizumab) Market Overview
• 21.2. Eastern Europe Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Tecentriq (Atezolizumab) Market

• 22.1. North America Tecentriq (Atezolizumab) Market Overview
• 22.2. North America Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Tecentriq (Atezolizumab) Market

• 23.1. USA Tecentriq (Atezolizumab) Market Overview
• 23.2. USA Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Tecentriq (Atezolizumab) Market

• 24.1. Canada Tecentriq (Atezolizumab) Market Overview
• 24.2. Canada Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Tecentriq (Atezolizumab) Market

• 25.1. South America Tecentriq (Atezolizumab) Market Overview
• 25.2. South America Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Tecentriq (Atezolizumab) Market

• 26.1. Middle East Tecentriq (Atezolizumab) Market Overview
• 26.2. Middle East Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Tecentriq (Atezolizumab) Market

• 27.1. Africa Tecentriq (Atezolizumab) Market Overview
• 27.2. Africa Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Tecentriq (Atezolizumab) Market Competitive Landscape And Company Profiles

• 28.1. Tecentriq (Atezolizumab) Market Competitive Landscape
• 28.2. Tecentriq (Atezolizumab) Market Company Profiles
  • 28.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

29. Global Tecentriq (Atezolizumab) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Tecentriq (Atezolizumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Tecentriq (Atezolizumab) Market

32. Recent Developments In The Tecentriq (Atezolizumab) Market

33. Tecentriq (Atezolizumab) Market High Potential Countries, Segments and Strategies

• 33.1 Tecentriq (Atezolizumab) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Tecentriq (Atezolizumab) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Tecentriq (Atezolizumab) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer